-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sickle cell anemia (SCD) is an autosomal dominant hemoglobinopathy characterized by a vascular occlusive crisis and acute pain.
Vascular FDA Prevents Children
Recently, researchers have re-evaluated the efficacy of Poloxamer 188 in the treatment of SCD vascular occlusion.
Recently, researchers have re-evaluated the efficacy of Poloxamer 188 in the treatment of SCD vascular occlusion.
The Phase III clinical study was carried out in 66 hospitals in 12 countries.
The average age of the patients was 15.
The study found that there was no significant difference in the time from the group to the last opioid injection (81.
Studies have found that for adults and children with sickle cell anemia, intravenous poloxamer 188 cannot shorten the duration of painful vascular occlusion .
For adults and children with sickle cell anemia, intravenous poloxamer 188 cannot shorten the duration of painful vascular occlusion .
Original source
James F.
com/journals/jama/article-abstract/2778807" target="_blank" rel="noopener">Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease A Randomized Clinical Trial.
JAMA Leave a message here
